Type 2 diabetes mellitus
Conditions
Interventions
Anagliptin 100mg-200mg x 2/day
Sponsors
Ikuo Inoue
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Type 2 diabetic patients, who has inadequate glycemic control, being treated with on diet and exercise or oral hypoglycemic agent 2) HbA1c<8.0% 3) More than 20 years (at the time of informed consent date) 4) Ability to provide written informed consent for this study
Exclusion criteria
Exclusion criteria: 1) The patient who uses DPP-4 inhibitor 2) The patient who uses Insulin 3) The patient who uses glinide 4) The patient who uses GLP-1 receptor agonist 5) The patient with hypersensitivity for anagliptin 6) The patient with severe diabetic ketoacidosis, with diabetic coma/precoma or with type 1 diabetes 7) The patient with sepsis, before and after operation, severe trauma 8) The patient with severe renal dysfunction (SCr:more than 2.4mg/dL (male), 2.0mg/dL(female)), hemodialysis or peritoneal dialysis 9) Female patients who are pregnant, suspected of being pregnant 10) Any patients deemed by the investigator to be ineligible for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is changes in LDL-cholesterol at 6 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is changes on plasma lanosterol, sitosterol, campesterol level in patients with type 2 diabetes mellitus | — |
Countries
Japan
Contacts
Public ContactIkuo Inoue
Saitama Medical University Department of Endocrinology and Diabetes
Outcome results
None listed